Search results
25 cze 2020 · This ESMO Clinical Practice Guideline provides key recommendations on the management of prostate cancer. •. Authorship includes a multidisciplinary group of experts from different institutions and countries in Europe. •. Key treatment recommendations are provided. •. Recommendations have been updated in the light of new evidence. Key words.
7 lis 2020 · Combining prostate-specific antigen density (PSAD) with the PI-RADS score may help define patients who need biopsy. In patients with negative mpMRI findings (PI-RADS 1–2), the risk of finding csPCa at subsequent SBx is usually ≤10% if the PSAD is <0.15 ng/mL/cc.
diagnosis and pathology. The risk of clinically significant prostate cancer is related to age, ethnicity, family history, PSA level, free/total PSA ratio and findings on digital rectal examination (DRE) [4]. High-grade prostate cancer can occur in men with a ‘normal’ PSA level.
The panel identified eight critical outcomes needed to inform the recommendations: all-cause mortality; prostate cancer mortality; incidence of prostate cancer diagnoses (all stages); incidence of localised cancer (stage I and II); incidence of advanced cancer (stage III and IV); complications from biopsies (such as bleeding, pain, infections ...
15 gru 2021 · This guideline covers the diagnosis and management of prostate cancer in secondary care, including information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment.
Your prostate biopsy results will show if any cancer was found and how aggressive it is (how likely it is to spread outside the prostate). You might hear this called your Gleason grade, Gleason score or grade group.
27 maj 2021 · After a diagnosis of prostate cancer is reached, further staging may be required and can be achieved by a variety of imaging techniques such as computed tomography (CT), bone scintigraphy, and prostate specific membrane antigen-based positron-emission tomography/CT.
